Ocugen posts Q1 loss, details positive Phase 2 GA data, prices $115M notes

Ocugen, Inc.

Net loss of $(0.06) per share for Q1 2026; cash, cash equivalents, and restricted cash of $32.2M as of March 31, 2026.
Phase 2 OCU410 trial for GA showed statistically significant 31% reduction in lesion growth at 12 months with optimal dose; 20% of patients showed no progression.
Enrollment completed for OCU400 Phase 3 RP trial (N=140) and OCU410ST Stargardt Phase 2/3 trial (N=63); BLA submissions targeted by 2027.
Priced $115M (up to $130M with over-allotment) of 6.75% Convertible Senior Notes due 2034 at 90% of par; conversion premium of 45% at $2.68/shr.
Net proceeds ~$99.5M; $32.7M to repay Avenue debt (12.5% interest); expected to extend cash runway into 2028.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ocugen, Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-055411

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.